

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN ¹—Continued

21 CFR section; activity	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Use of veterinary master files during all phases of product development (including product development that precedes the establishment of an INAD file or the submission of a NADA)	15	1	15	20	300
Total			1,022		22,083

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

² NADAs and supplements regarding antimicrobial animal drugs that use a recommended approach to assessing antimicrobial concerns as part of the overall preapproval safety evaluation.

Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our previous estimates. However, as discussed, we have separately estimated the burden of the “Use of veterinary master files during all phases of product development (including product development that precedes the establishment of an INAD file or the submission of a NADA)” in table 1, row 10. We base our estimate of the total annual responses for the use of veterinary master files on such uses initiated during calendar year 2018. We base our estimate of the hours per response upon our experience with the respondents’ use of veterinary master files. We estimate that the time it takes to compile information and submit it to a veterinary master file will vary from 1 to 50 hours, depending on the complexity of the information; therefore, we are estimating on average the burden per response to be 20 hours. Accordingly, we report an additional 300 burden hours and 15 total annual responses in row 10. We are also correcting several rounding errors that were made in our last request for OMB approval. Correcting these rounding errors reduces our previously reported total burden hours and total responses. Thus, our estimated burden for the information collection reflects a net overall increase of 124 hours and a corresponding increase of 14 responses.

Dated: February 11, 2019.

Lowell J. Schiller,

Acting Associate Commissioner for Policy.

[FR Doc. 2019–02479 Filed 2–14–19; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Advisory Council on Blood Stem Cell Transplantation

AGENCY: Health Resources and Services Administration (HRSA), the Department of Health and Human Services (HHS).

ACTION: Notice of charter renewal.

SUMMARY: HHS is hereby giving notice that the Advisory Council on Blood Stem Cell Transplantation (ACBSCT) has been renewed. The effective date of the renewed charter is February 19, 2019.

FOR FURTHER INFORMATION CONTACT:

Robert Walsh, Executive Secretary, ACBSCT, HRSA, 5600 Fishers Lane, Rockville, Maryland 20857. Phone: 301–443–6839; email: rwalsh@hrsa.gov.

SUPPLEMENTARY INFORMATION: Relevant statutes are Public Law 109–129 as amended by Public Law 111–264; 42 U.S.C. 274k; and Section 379 of the Public Health Service Act. The Council is governed by the provisions of Public Law 92–463, as amended (5 U.S.C. appendix 2), which sets forth standards for the formation and use of advisory committees.

ACBSCT advises and makes recommendations to the Secretary of Health and Human Services (Secretary) on matters related to the activities of the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory Program. One of its principal functions shall be to provide consolidated, comprehensive sources of expert, unbiased analysis and recommendations to the Secretary on the latest advances in the science of blood stem cell transplantation.

ACBSCT may meet up to three times during the fiscal year. The charter renewal for ACBSCT was approved on February 7, 2019. The filing date is February 19, 2019. Renewal of the

ACBSCT charter authorizes the Council to operate until February 19, 2021.

A copy of the ACBSCT charter is available on the ACBSCT website at: https://bloodcell.transplant.hrsa.gov/about/advisory_council/index.html. A copy of the charter can also be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is <http://www.facadatabase.gov/>.

Amy P. McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2019–02399 Filed 2–14–19; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Retail Pharmacy Interest in Utilization of Innovative Educational Technology To Increase Human Papillomavirus (HPV) Vaccination Rates in Rural Areas

AGENCY: National Vaccine Program Office, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: This request for information (RFI) is issued for informational and planning purposes only. This RFI is not a solicitation; nor does it commit the Department of Health and Human Services (HHS) to issue a solicitation, make any award, or pay any costs associated with responding to this announcement.

The RFI is being issued by the National Vaccine Program Office (NVPO) of the U.S. Department of Health and Human Services. The NVPO is located in the Office of the Assistant Secretary for Health (ASH), Office of the Secretary (OS), U.S. Department of Health and Human Services (HHS). The NVPO provides strategic leadership and

management, policy scholarship and recommendations, and encourages collaboration and coordination among federal agencies and other stakeholders whose mission is to reduce the burden of preventable infectious disease through immunization. NVPO offers thorough reporting, unbiased advice and expertise to other agencies in identifying and responding to gaps in the vaccine system.

Prevention of cancers associated with Human Papillomavirus (HPV) infections continues to be a public health challenge in the United States. Vaccination is an effective, primary medical intervention for prevention of infection from these viruses. Despite this, HPV vaccination series completion rates remain low nationwide, with adolescents living in rural communities (per census definition of <50,000 population) having a significantly lower HPV vaccination coverage when compared to their urban or suburban counterparts.

In accordance with policy recommendations from the National Vaccine Advisory Committee and efforts to promote HPV-vaccination coverage in rural areas, NVPO is seeking information on the level of interest of retail pharmacies in utilizing innovative educational models for both providers and customers to increase HPV-vaccination rates in rural areas.

DATES: Information from retail pharmacies with greater than 100 stores in geographic areas considered to be rural by the census definition (<50,000 population) should submit responses to this RFI as described in the addresses section below no later than midnight, 12:00 a.m. EDT on February 25, 2019.

ADDRESSES: Responses should be submitted in Portable Document Format (PDF) only and be sent via email to nvpo@hhs.gov. The name(s) of all PDF files uploaded should begin with "NVPO_RFI_Pharmacy" followed by the organization name and the sequential number of the file, if more than one file is submitted. All submissions responsive to this RFI must be made as indicated above. Mailed paper submissions will not be reviewed.

FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, Office of the Assistant Secretary for Health, Department of Health and Human Services; telephone (202) 690-5566; email: nvpo@hhs.gov.

SUPPLEMENTARY INFORMATION: Responses to this RFI should be in the format outlined below. Primary responses should be limited to no more than 30 pages, 12 point, Times New Roman font, using a minimum of one-inch margins.

Supplementary material may be included in appendices and will not count toward the page limitation.

Section 1—General Information

Responses to this RFI should include (1) the organization's full name, (2) headquarters location, and (3) a description of interest level in utilizing innovative educational models for both providers and customers to increase HPV vaccine series completion and thereby lower vaccine preventable HPV-associated cancers.

Section 2—Qualifications and Experience

Provide a description of corporate experience in developing and/or implementing innovative educational models for both (1) retail pharmacy providers, and (2) customers as part of health messaging, *i.e.* to increase vaccination rates.

Section 3—Recommendations for Execution

Provide recommendations or lessons learned while developing and/or implementing an innovative educational model for retail pharmacy providers and customers to increase HPV-vaccination rates.

Section 4—Likelihood of Participation

Comment on the likelihood of your firm to submit a proposal for the utilization of innovative educational technology to increase HPV vaccination rates in rural areas.

Companies are invited to respond to this request for information if they meet at least three of the following criteria:

1. Are a national retail pharmacy with greater than 100 stores in geographic areas considered to be rural by the census definition (<50,000 population)
2. Are a national employer
3. Have an immunization provider (*i.e.* nurse, pharmacist, physician) on site in their stores
4. Stores must stock and administer Human Papillomavirus (HPV) vaccine
5. Have existing virtual reality (VR) platform employee training in place
6. Have both brick-and-mortar locations and a website by which consumers can make purchases
7. Have existing patient/consumer health education campaigns
8. Have a least one site with the designation of 'Centers of Excellence in Specialized Pharmacy Care'

Responders should include point-of-contact information including email and postal mailing address.

Responses to any of the above areas are welcome; respondents are not

required to address all the issues identified in the request. Public release of the data submitted is governed by the Freedom of Information Act (<https://www.hhs.gov/foia/>). Response to the RFI will not be returned.

Dated: February 1, 2019.

Tammy Beckham,

Acting Director, National Vaccine Program Office.

[FR Doc. 2019-02548 Filed 2-14-19; 8:45 am]

BILLING CODE 4150-44-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Allergy, Immunology, and Transplantation Research Committee; Allergy, Immunology, and Transplantation Research Committee (AITC) September 2019 Council.

Date: June 13–14, 2019.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: James T. Snyder, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G31B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892–9834, (240) 669–5060, james.snyder@nih.gov.

Name of Committee: Allergy, Immunology, and Transplantation Research Committee; Allergy, Immunology, and Transplantation Research Committee (AITC) January 2020 Council.

Date: October 24–25, 2019.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).